new glp 1 drugs in development Market Overview: GLP-1 Agonists and the Obesity Market | Blog Science's 2023 Breakthrough: GLP-1R Agonists
Description
This company has it together
Bottom line GLP-1 medications, or glucagon-like peptide-1 receptor agonists, treat type 2 diabetes and, in some cases, obesity
Safety profiling of GLP-1 therapy Studies have found that GLP-1 agonists are associated with increased risk of gastrointestinal adverse events spanning from nausea and vomiting to pancreatitis and kidney dysfunction
The drug never fixed the dysregulated systems
Kim, PhD
